Pagina inicial
Continue Watching
Últimos vídeos
Últimos vídeos
Brightcove Home Latest Listing
Oncology
Oncology
Brightcove Cards Listing
Hematology
Hematology
Brightcove Cards Listing
Popular em MedEnrich
Popular em MedEnrich
Popular in Sem nome
Oncology1m 36s
Enhancing Global Access to Cancer Medicines
Over the last decade we have seen emergence of increasing novel therapies like targeted therapy and immunotherapy & this has changed the natural history of disease for patients living with cancer including those with advanced disease.
biosimilars
access
generics
1![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1721729333_7c0545a41c7fdb43.jpg.webp?itok=3bpx7pMg)
![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1721729333_7c0545a41c7fdb43.jpg.webp?itok=3bpx7pMg)
Enhancing Global Access to Cancer Medicines
Myelodysplastic Syndromes3m 14s
Low Risk MDS - Key Practice Points
Myelodysplastic Syndromes (MDS) or Myeloproliferative Neoplasms show considerable heterogeneity with respect to presence of anemia , cytopenia & molecular features.
ipss -m
low risk
molecular features
1![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1721738312_7d5ccb0ad609512c.jpg.webp?itok=49CPBxmK)
![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1721738312_7d5ccb0ad609512c.jpg.webp?itok=49CPBxmK)
Low Risk MDS - Key Practice Points
3m 36s
Tumor Infiltrating Lymphocytes as Predictive Biomarker in Breast Cancer
Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.
tumor-infiltrating lymphocytes (tils)
promising biomarker
1![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1720085526_6c30bedcc918dfbb.jpg.webp?itok=RtSvcvnu)
![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1720085526_6c30bedcc918dfbb.jpg.webp?itok=RtSvcvnu)
Tumor Infiltrating Lymphocytes as Predictive...
3m 36s
Tumor Infiltrating Lymphocytes as Predictive Biomarker in Breast Cancer
Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.
tumor-infiltrating lymphocytes (tils)
promising biomarker
1![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1720085526_6c30bedcc918dfbb.jpg.webp?itok=RtSvcvnu)
![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1720085526_6c30bedcc918dfbb.jpg.webp?itok=RtSvcvnu)
Tumor Infiltrating Lymphocytes as Predictive...
"NA"11m 43s
Sequencing of treatment for Her2 positive MBC in 2022
Noteworthy treatment options added in the treatment guidelines for Her2 positive MBC are Trastuzumab Deruxtecan (TDXd) and combination of Trastuzumab + Capecitabine +Tucatinib.
brain metastases
her2 positive mbc
trastuzumab deruxtecan
tucatinib
1![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1721219905_85a7f757d13a1e19.jpg.webp?itok=-duX4J2y)
![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1721219905_85a7f757d13a1e19.jpg.webp?itok=-duX4J2y)
Sequencing of treatment for Her2 positive MBC in...
Multiple-Myeloma0m 53s
Importance of identifying High Risk Patients in Multiple Myeloma
High risk disease is observed in 30% of Myeloma Cases. Identification of high-risk patients is important as proportion of high-risk cases increase with relapses and can lead to significant mortality.
high risk myeloma
1![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1721718337_3bdb869dda66a865.jpg.webp?itok=iokOIq9s)
![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1721718337_3bdb869dda66a865.jpg.webp?itok=iokOIq9s)
Importance of identifying High Risk Patients in...
Mieloma múltiplo4m 12s
Key Practice Points -Myeloma Related Renal Impairment
In patients with renal impairment primary goal is improvement of Renal Function which is associated with improved treatment outcomes. 50% of patients present renal impairment and renal impairment is severe in 15% of patients.
myeloma
renal impairment
key practice points
1![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1721244738_58fa83a1137649cb.jpg.webp?itok=P4j4rzDt)
![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1721244738_58fa83a1137649cb.jpg.webp?itok=P4j4rzDt)
Key Practice Points -Myeloma Related Renal...
Mieloma múltiplo10m 40s
Recommendations -Management of Myeloma Related Renal Impairment
Supportive Care, Mechanical Approach and Systemic Antimyeloma treatment are 3 pillars of management of Myeloma related renal impairment. In supportive care prompt initiation of high fluid administration, appropriate use of Bisphosphonates can help.
myeloma
renal impairment
lancet guidelines
1![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1722333725_71d1bb3b6b330c43.jpg.webp?itok=BQQRR8Xm)
![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1722333725_71d1bb3b6b330c43.jpg.webp?itok=BQQRR8Xm)
Recommendations -Management of Myeloma Related...
Myelodysplastic Syndromes31m 24s
Improving Diagnosis of MDS -Innovative Solutions
Modern Web -Based digital tools based on 10 routinely used clinical parameters and Gradient Based Model can help in non-invasive diagnosis of MDS.
mds diagnosis
web based diagnosis
her2negative mbc
1![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1721263139_6352532c9da76775.jpg.webp?itok=-bE_8Emx)
![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1721263139_6352532c9da76775.jpg.webp?itok=-bE_8Emx)
Improving Diagnosis of MDS -Innovative Solutions
29m 30s
SABCS Update 2022
Summary of Key Abstracts from SABCS 2022
recurrence score
tailor-x
destiny breast 03
adjuvant cdk4/6 inhibitor
antibody drug conjugates
1![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1721738332_b393d3b105368c05.jpg.webp?itok=6bP8ih1l)
![](/brazil/sites/g/files/nstucr146/files/styles/popular_video_thumbnail/public/brightcove/videos/images/posters/1721738332_b393d3b105368c05.jpg.webp?itok=6bP8ih1l)